Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Therapeutics plc - American Depositary Shares (NQ: ADAP )

0.5833 -0.0047 (-0.80%)
Streaming Delayed Price Updated: 11:51 AM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 344,374
Open 0.5810
Bid (Size) 0.5800 (18)
Ask (Size) 0.5833 (8)
Prev. Close 0.5880
Today's Range 0.5751 - 0.5900
52wk Range 0.5005 - 2.050
Shares Outstanding 1,535,299,242
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31,... 
Via Newsfile
Topics Initial Public Offering
Exposures Securities Market
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company... 
Via Newsfile

Performance

YTD
-21.81%
-21.81%
1 Month
-16.32%
-16.32%
3 Month
-37.82%
-37.82%
6 Month
-33.76%
-33.76%
1 Year
-0.19%
-0.19%

More News

Read More
Demystifying Adaptimmune Therapeutics: Insights From 4 Analyst Reviews
Via Benzinga
Adaptimmune Reports Q3 2024 Financial and Business Updates
Via Newsfile
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
Via Newsfile
Earnings Scheduled For November 13, 2024
Via Benzinga
An Overview of Adaptimmune Therapeutics's Earnings
Via Benzinga
The Latest Analyst Ratings For Adaptimmune Therapeutics
Via Benzinga
Why Adaptimmune Therapeutics (ADAP) Stock Is Moving
Via Benzinga
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Via Newsfile
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
Via Newsfile
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
From Virtual Investor Conferences
Via GlobeNewswire
Adaptimmune to Participate in Two Bank Conferences this September
Via Newsfile
ADAP Stock Earnings: Adaptimmune Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Adaptimmune Reports Q2 2024 Financial and Business Updates
Via Newsfile
Exposures Product Safety
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
Via Benzinga
Exposures Product Safety
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
From Adaptimmune Therapeutics plc
Via Business Wire
3 Biotech Moonshots With Imminent Catalyst Potential
Via InvestorPlace
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
Via Newsfile
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
Via AB Newswire
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.